Results 231 to 240 of about 198,039 (308)

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

The effects of neoadjuvant sintilimab versus pembrolizumab combined with chemotherapy on resectable non-small cell lung cancer: a multicenter propensity score-matched study. [PDF]

Transl Lung Cancer Res
Sun Y, Gao Z, Luo Z, Tong L, Zhang Y, Dong X, Wang J, Li W, Li Z, Qiao W, Chen X, Duan H, Yan X.   +12 more
europepmc   +1 more source

Data Sheet 1_Response to dabrafenib and trametinib combined with pembrolizumab in an elderly patient with lung adenocarcinoma of unknown primary harboring BRAF V600E mutation and high PD-L1 expression: a case report.pdf

Nan Li (155066), Jing Hu (41899), Guangjin Bao (22629794), Zhigang Cai (695459)   +3 more
openalex   +1 more source

Precision medicine in cutaneous melanoma—A comprehensive review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions. [PDF]

Front Immunol
Lian M, Zhang C, Li T, Wang A.
europepmc   +1 more source

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting [PDF]

Emma L. Myers, Jessica Liu, Sabrina M Shearer, Sarah A. Myers, Michelle Schneider, Christopher Hoimes, Melodi Javid Whitley   +6 more
openalex   +1 more source

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta, Tong Wang, Susmita, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +5 more
wiley   +1 more source

Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective Study.

Acta Derm Venereol
Goller S, Dege T, Schummer P, Haug L, Meir M, Gehrke T, Klein D, Goebeler M, Kneitz H, Schilling B, Gesierich A, Glutsch V.   +11 more
europepmc   +1 more source

Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma. [PDF]

Front Immunol
Ajani JA, Smyth E, Tougeron D, Jung HA, Tang W, Steenkamp J, Prentiss E, Coaquira Castro J, Szafranski K, Zhan L.   +9 more
europepmc   +1 more source

Exceptional Response to Pembrolizumab in Metastatic ER+/HER2− Breast Cancer With Liver Metastases: A Case Report and Literature Review [PDF]

Claudia Villa Celi, Supriya Peshin, Adit Dharia, Faizan Bashir, L. Clinkenbeard Erica   +4 more
openalex   +1 more source